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Sure Start in England
Abstract
In her Comment (Nov 8, p 1610) on our second phase of evaluation of Sure Start local programmes in
England, Penny Kane makes several points with which we could not agree more. Like her, we would have
much preferred to see a randomised controlled trial done, since this would have afforded much stronger causal
inferences than the quasi-experimental investigation we undertook. We also agree that the fact that we drew
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safety of the tested drugs were not 
diff erent between patients with and 
without diabetes. We recorded the 
glycaemic and glycosylated haemo-
globin values at baseline and during 
the 3·9 years of average follow-up. As 
for glitazones, their use is not exten-
sive in Italy, but we did not specifi cally 
record this treatment.
Christopher Florkowski and col-
leagues again bring up the hypothesis 
that a reduction in coenzyme Q10 
induced by statins might mask the 
potential benefi ts of these drugs in 
patients with heart failure. Actually 
the Q10 argument was usually a 
safety concern, yet rosuvastatin 
seemed to be safe in GISSI-HF as 
well as in the CORONA trial.3 As for 
effi  cacy, although the possibility that 
a potential benefi t from statins might 
be concealed by a decrease in Q10 
production cannot be ruled out, the 
perspective of admistering two drugs, 
one to counteract the negative eff ect 
of the other, to elderly patients with 
heart failure, who are probably already 
on multiple drugs, does not seem too 
promising.
Vincenzo Solfrizzi and coauthors 
seem to consider the GISSI-HF popu-
lations too heterogeneous, with frail 
elderly patients being over-repre-
sented. However, in the GISSI-HF 
population, two-thirds were of New 
York Heart Association (NYHA) class 
II and the remaining third were class III 
patients with a mean age of 67 years 
(the median age of patients with 
chronic heart failure being around 
75 years). Accordingly, the criticism 
looks unfounded.
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Sure Start in England
In her Comment (Nov 8, p 1610)1 
on our second phase of evaluation 
of Sure Start local programmes in 
England,2 Penny Kane makes several 
points with which we could not 
agree more. Like her, we would have 
much preferred to see a randomised 
controlled trial done, since this 
would have aff orded much stronger 
causal inferences than the quasi-
experimental investigation we under-
took. We also agree that the fact 
that we drew on data collected by 
two diff erent research teams raises 
questions about the confi dence that 
can be placed in conclusions drawn. 
Indeed, these were points we made 
in our original report.
We remain agnostic as to whether 
the positive effects of Sure Start 
local programmes we detected 
were insufficient to be of policy 
importance or should have emerged 
on other child outcomes such as 
verbal ability, especially in so short 
a time frame (ie, when children are 
3 years old). Open-minded scholars 
can have honest disagreements on 
this issue.
We are continuing to follow up the 
children and families to determine 
whether, at age 5 years, the eff ects 
detected at age 3 years have been 
maintained, dissipated, or changed 
in some manner. We look forward to 
reporting on this matter in the not-
too-distant future.
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The UK’s system of general practice, 
based on the long-term registered 
population, is one of the most popular, 
successful, and effi  cient ways of de-
livering primary health care. It allows 
for continuity of care, a multidis-
ciplinary approach, and a systematic 
integra tion of individual and family 
acute health care with risk manage-
ment, preven tive inter ventions, and 
care of long-term disorders. How tragic 
that the potential of this horizontal 
approach, so often shown to be 
successful, has been ignored by the 
vertical approach in relation to health 
care embodied in children’s centres 
and the Sure Start programme.
I work in a large general-practice 
team that includes doctors, nurses, 
and child health visitors, in a health 
centre owned by the National Health 
Service. I walked 200 m down the 
street to discover a children’s centre 
under construction, of which none of 
us was aware. Although the additional 
support for families and children from 
psychology to baby massage is very 
welcome, it is no surprise that this 
separate programme is associated 
with lower child immunisation 
rates.1,2 Immunisation normally takes 
place in general practice, where Sure 
Start has no structural input.
This has been a missed opportunity 
for strengthening children’s services 
through horizontal integration of 
social services with primary health 
care, and is ironic at a time when the 
UK government has been promoting 
polyclinics in the community. 
Development is always needed. I hope 
it is not too late to grow together.
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